Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
10 search results for:

CD 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 27-01-2020 | Rheumatoid arthritis | News | Article

    CDAI nonresponse at 3 months predicts late certolizumab pegol failure in RA

    Real-world findings suggest that nonresponse to certolizumab pegol based on CDAI scores at 3 months is a good indicator that patients with rheumatoid arthritis are unlikely to achieve the therapeutic target of low disease activity at 1 year.

    Author:
    Hannah Kitt
    Published in:
    RMD Open 2020; doi:10.1136/rmdopen-2019-000991
  2. 01-05-2019 | Rheumatoid arthritis | News | Article

    CD40L blockade shows promise for RA

    Findings from a proof-of-concept study provide preliminary evidence that the CD40 ligand binding agent VIB4920 may be a promising treatment option for rheumatoid arthritis.

    Published in:
    Sci Transl Med 2019; 11 : eaar6584
  3. 25-04-2018 | Giant cell arteritis | Article

    CD3 immunohistochemistry is helpful in the diagnosis of giant cell arteritis

    Ciccia F et al. Rheumatology (Oxford) 2018; Advance online publication. doi: 10.1093/rheumatology/key106

  4. 07-11-2017 | Sjögren’s syndrome | ACR/ARHP 2017 | Article
    News in brief

    CD40 blockade shows promise in Sjögren’s syndrome

    Phase IIa trial results suggest that treatment with the anti-CD40 monoclonal antibody CFZ533 improves disease activity and is well tolerated in patients with clinically active primary Sjögren’s syndrome.

  5. 18-08-2017 | Systemic lupus erythematosus | News | Article

    Hopes revived for CD40L blockade in SLE

    Phase I trial results suggest that the CD40 ligand inhibitor dapirolizumab pegol is well tolerated and elicits a clinical response in patients with systemic lupus erythematosus.

    Published in:
    Ann Rheum Dis 2017; Advance online publication
  6. 30-05-2019 | Arthroplasty | News | Article
    approvalsWatch

    FDA approves first diagnostic test for joint replacement infections

    The assay, called the Synovasure Lateral Flow Test Kit (CD Diagnostics Inc., Claymont, Delaware, USA), measures alpha defensins released by neutrophils in the synovial fluid, indicating the presence of infection.

  7. 03-05-2018 | Systemic lupus erythematosus | Article

    Meta-analysis of GWAS on both Chinese and European populations identifies GPR173 as a novel X chromosome susceptibility gene for SLE

    Kaufman KM, Zhao J, Kelly JA, Hughes T, Adler A, Sanchez E, Ojwang JO, Langefeld CD, Ziegler JT, Williams AH, et al.

  8. 06-06-2016 | Gout | Article

    A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout

    This paper examines reasons for lack of urate-lowering therapy (ULT) in many patients with gout, using patient interviews to explore patient experience with, and understanding of, such therapy. Richardson JC, Liddle J, Mallen CD, Roddy E, Hider S, Prinjha S, Ziebland S.  BMC Musculoskelet Disord . 2016;17:249. doi: 10.1186/s12891-016-1117-5.

  9. 08-02-2016 | Microbiome | Article

    Intestinal Microbiota Distinguish Gout Patients from Healthy Humans

    A non-redundant gene catalogue was constructed with CD-HIT 38 using a sequence indentity cut-off of 0.95, with a minimum coverage cut-off of 0.9 for the shorter sequences.

    Author:
    Zhuang Guo, Jiachao Zhang, Zhanli Wang, Kay Ying Ang, Shi Huang, Qiangchuan Hou, Xiaoquan Su, Jianmin Qiao, Yi Zheng, Lifeng Wang, Eileen Koh, Ho Danliang, Jian Xu, Yuan Kun Lee, Heping Zhang
  10. 13-06-2018 | Osteoarthritis | Review | Article

    Molecular transport in articular cartilage: What have we learned from the past 50 years?

    DiDomenico CD, Lintz M, Bonassar LJ. Nat Rev Rheumatol 2018; 14: 393–403. doi: 10.1038/s41584-018-0033-5

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.